Kura Oncology (KURA) Current Leases (2019 - 2026)
Kura Oncology (KURA) posted quarterly Current Leases of $1.3 million for Q1 2026, down 32.65% year-over-year from $1.9 million in Q1 2025, and little changed quarter-over-quarter from $1.3 million in Q4 2025.
Kura Oncology (KURA) Current Leases (2019 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Current Leases for 8 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 32.65% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 32.65% YoY), while the FY2025 annual figure was $1.3 million, down 32.11% from the prior year.
- Current Leases was little changed at $1.3 million in Q1 2026 per KURA's latest filing, from $1.3 million in the prior quarter.
- Across five years, Current Leases topped out at $2.3 million in Q2 2023 and bottomed at $1.3 million in Q4 2025.
- Historically, Current Leases has averaged $1.8 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2024 — Current Leases sank 41.55% — and 2025, when it jumped 39.77%.
- Kura Oncology's Current Leases stood at $2.3 million in 2022, then plunged by 35.03% to $1.5 million in 2023, then grew by 24.9% to $1.9 million in 2024, then slumped by 32.11% to $1.3 million in 2025, then grew by 0.47% to $1.3 million in 2026.
- Business Quant data shows KURA's Current Leases at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 2.32 Mn |
| Sep 30, 2022 | 2.30 Mn |
| Jun 30, 2022 | 2.29 Mn |
| Mar 31, 2022 | 2.28 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 2.25 Mn |